Inactief instrument

Andere talen OKYO Pharma Limited London S.E.

Aandelen

OKYO

GG00BMFG5F62

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)	30/04
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024	09/04
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery	02/04
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	22/03
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	22/03
OKYO Pharma Limited to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial	20/03
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event	20/03
Sector Update: Health Care Stocks Mixed in Afternoon Trading	09/02
Sector Update: Health Care	09/02
OKYO Pharma Rising After FDA Approves Phase 2 Trial of Prospective Treatment for Cornea Eye Pain	09/02
Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	09/02
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	09/02
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board	31/01
OKYO Pharma Limited Announces Appointment of Scientific Advisory Board	31/01
OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease	08/01
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease	08/01
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024	05/01
OKYO PHARSADR : INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K - Form 6-K	18/12
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit	04/12
Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit	04/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen OKYO Pharma Limited London S.E.

Aandelen

OKYO

GG00BMFG5F62

Andere talen

Filters